Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Other Agents for Treating Myeloma

January 23rd 2018

Impact of MRD Assessment on Myeloma Treatment

January 23rd 2018

The Role of MRD Testing in Myeloma

January 23rd 2018

Adding Carfilzomib to R/R Myeloma Regimens

January 23rd 2018

Impact of Elotuzumab in R/R Myeloma Therapies

January 23rd 2018

Daratumumab-Based Regimens in R/R Myeloma

January 23rd 2018

The Role of Transplant in Myeloma

January 23rd 2018

Impact of Maintenance Therapy in Myeloma

January 23rd 2018

Upfront Combination Therapies in Myeloma

January 23rd 2018

Upfront Therapy Approaches in Myeloma

January 23rd 2018

Managing High-Risk Smoldering Myeloma

January 23rd 2018

Risk Assessment for Myeloma

January 23rd 2018

FDA Grants Priority Review to Frontline Daratumumab for Multiple Myeloma

January 22nd 2018

The FDA has granted a priority review designation to daratumumab in combination with bortezomib, melphalan, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Dr. Wolf Emphasizes the Importance of Maintenance Therapy in Patients With Myeloma

January 18th 2018

Jeffrey Wolf, MD, clinical professor, Department of Medicine, director, Myeloma Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, details the role maintenance therapy has in treating patients with myeloma.

Dr. Richter on Study of Symptom Management in Multiple Myeloma

January 18th 2018

Joshua Richter, MD, a hematologist/oncologist specializing in multiple myeloma at the John Theurer Cancer Center discusses symptom management in patients with multiple myeloma.

FDA Approves Carfilzomib Label Update in Myeloma

January 18th 2018

The FDA has approved a supplemental new drug application that adds overall survival data from the phase III ENDEAVOR trial to the label for carfilzomib for use in patients with relapsed or refractory multiple myeloma.

Emerging Therapies Generate Excitement in Myeloma

January 17th 2018

Thomas G. Martin, MD, discusses emerging advancements in the treatment landscape of multiple myeloma.

Dr. Martin on Choosing Treatments for Multiple Myeloma

January 16th 2018

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, University of California, San Francisco; co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses choosing treatments for patients with multiple myeloma.

Dr. Gasparetto on Next Steps With Selinexor and Daratumumab in Multiple Myeloma

January 8th 2018

Cristina Gasparetto, MD, assistant professor of medicine, member of the Duke Cancer Institute, discusses the next steps with selinexor and daratumumab (Darzalex) in multiple myeloma.

Dr. Martin on FDA Approval of Denosumab in Multiple Myeloma

January 5th 2018

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, University of California, San Francisco; co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses the FDA approval of denosumab (Xgeva) for the prevention of skeletal-related events in patients with multiple myeloma.